(Q46600220)

23 December 2017

review article

1 reference

title

Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis (English)

1 reference

23 December 2017

1 reference

1 reference

1 reference

Juan Carlos Montejo González

series ordinal

1

1 reference

23 December 2017

Mercedes Catalán González

series ordinal

2

1 reference

23 December 2017

Cristóbal León Gil

series ordinal

3

1 reference

23 December 2017

publication date

1 June 2008

1 reference

23 December 2017

Revista iberoamericana de micologia

published in

1 reference

23 December 2017

volume

25

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

page(s)

107-118

1 reference

23 December 2017

Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Pharmacology of Systemic Antifungal Agents

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Effects of nosocomial candidemia on outcomes of critically ill patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Lack of pharmacokinetic interaction between anidulafungin and tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

The epidemiology of sepsis in the United States from 1979 through 2000

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Antifungal use in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Global trends in candidemia: review of reports from 1995-2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Anidulafungin and fluconazole for candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Invasive candidiasis in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

New approaches to the risk of Candida in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Guidelines for treatment of candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Anidulafungin versus fluconazole for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Candidemia in Norway (1991 to 2003): results from a nationwide study

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Invasive oesophageal candidiasis: current and developing treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Options for the management of mucosal candidiasis in patients with AIDS and HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Anidulafungin: a novel echinocandin

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2808%2970028-7

7 January 2021

10.1016/S1130-1406(08)70028-7

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017